This site is intended for healthcare professionals
Drug information

Colestid

POM
Read time: 7 mins
Last updated: 06 May 2020
Published: 01 Apr 2021

4.1 Therapeutic indications

Colestid is indicated as adjunctive therapy to diet in the management of patients with elevated cholesterol levels who have not responded adequately to diet. It may be used alone or in combination with additional lipid lowering agents.

Dietary therapy specific for the type of hypercholesterolemia should be the initial treatment of choice. Excess body weight may be an important factor and weight reduction should be attempted prior to drug therapy in the overweight. The use of drugs should be considered only when reasonable attempts have been made to obtain satisfactory results with non-drug methods. When drug therapy is begun, the patient should be instructed of the importance of adhering to the correct diet.

Although Colestid is effective in all types of hypercholesterolemia, it is medically most appropriate in patients with Fredrickson's type II hyperlipoproteinaemia.

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

 

 

Disclaimer

The drug SPC information (indications, contra-indications, interactions, etc), has been developed in collaboration with eMC (www.medicines.org.uk/emc/). Medthority offers the whole library of SPC documents from eMC.

Medthority will not be held liable for explicit or implicit errors, or missing data.

Reporting of suspected adverse reactions 

Drug Licencing

Drugs appearing in this section are approved by UK Medicines & Healthcare Products Regulatory Agency (MHRA), & the European Medicines Agency (EMA).